Pharmafile Logo
Pharmafocus logo
Advanced Search

Restasis

Showing 5 posts of 5 posts found.

allergan

Allergan and St Regis Mohawk Tribe take patent ruling to Supreme Court

January 28, 2019
Sales and Marketing Allergan, Mohawk, Restasis, St Regis, eye drops, patents

Allergan and the St Regis Mohawk Tribe have asked the Supreme Court to defend a 2017 patent agreement which would …

News
allergan

US court overturns Allergan’s controversial attempts to avoid Restasis patent review

July 23, 2018
Sales and Marketing Allergan, Mylan, Restasis, US, dry eye, pharma

The US Court of Appeals for the Federal Circuit has seen fit to authorise a US Patent and Trademark Office …

News

Rumours Allergan is looking to offload $5bn women’s health unit

April 3, 2018
Manufacturing and Production, Sales and Marketing Allergan, Restasis, biotech, drugs, pharma, pharmaceutical

According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move …

News
shire_image

Shire takes fight to Allergan over dry-eye drug

October 4, 2017
Research and Development Allergan, Restasis, Shire, biotech, drugs, pharma, pharmaceutical

It’s not long since Allergan was in the headlines over its dry-eye drug, Restasis, after an eye-catching attempt to avoid …

News
Ikervis

New treatments to boost dry eye drug market – if approved

November 5, 2015
Sales and Marketing Allergan, Ikervis, Restasis, Shire, cyclosporine, dry eye disease, dry eye syndrome, lifitegrast

The global market for treatments for dry eye syndrome will double in value to an estimated $4.6 billion by 2024, …

News

Latest content

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024